Life360, Inc. — Director's Dealing 2021

Sep 14, 2021

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Life360, inc.
ARBN	629 412 942

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

We (the entity) give ASX the following the director for the purposes of section	information under listing rule 3.19A.2 and as agent for 205G of the Corporations Act.
Name of Director	Alexander (Alex) Haro
Date of last notice	29 June 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	‐
Date of change	(i) 8 September 2021 (PDT) (ii) 3 June 2021 (PDT)
No. of securities held prior to change	 2,157,560 shares of common stock (Shares) (equivalent to 6,472,680 Chess Depositary Interests (CDIs)  386,938 Options overs Shares (Options)  91,905 CDIs held by ICCA Labs, LLC  1,798 Restricted Stock Units(RSUs)
Class	(i) Shares & RSUs (ii) Shares & CDIs
Number acquired	(i) 449 Shares (ii) 1,140,687 CDIs

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed	(i) 449 RSUs (having vested) (ii) 380,229 Shares (having transmuted)
Value/Consideration Note: If consideration is non‐cash, provide details and estimated valuation	(i) Shares are issued following the vesting and settlement of 449 RSUs, which were granted in lieu of the payment of Directors’ Fees1 (ii) Nil. Shares were converted to CDIs – no change in net holding and no consideration required for conversions.
No. of securities held after change	 1,777,780 Shares (equivalent to 5,333,340 CDIs)  1,140,687 CDIs  386,938 Options  91,905 CDIs held by ICCA Labs, LLC  1,349 RSUs
Nature of change Example: on‐market trade, off‐market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy‐back	(i) Issue of Shares following the vesting and settlement of RSUs. (ii) Conversion/transmutation of 380,229 Shares to 1,140,687 CDIs

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A

1 As per Appendix 3Y lodged on 7 May 2021, 2,462 RSUs were granted in lieu of the payment of US$32,867 of Director and Committee fees. RSUs vest and are settled quarterly.

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest disposed	N/A
Value/Consideration Note: If consideration is non‐cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3